Stifel Maintains Hold on Atara Biotherapeutics, Lowers Price Target to $2.3
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Benjamin Burnett has maintained a Hold rating on Atara Biotherapeutics (NASDAQ:ATRA) but has lowered the price target from $4.8 to $2.3.

April 01, 2024 | 2:56 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Stifel analyst maintains a Hold rating on Atara Biotherapeutics but lowers the price target from $4.8 to $2.3.
The reduction in the price target by Stifel indicates a negative outlook on the stock's short-term price potential, likely due to underlying challenges or revised expectations. This adjustment can influence investor sentiment and potentially lead to a decrease in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100